Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Exploring Transcriptional alterations in the Development of Gemcitabine Resistance [SW1990R_vs_SW1990_RNAseq]

ABSTRACT: To investigate the transcriptional alterations that occur during the development of gemcitabine resistance in pancreatic cancer cells, we established gemcitabine-resistant SW1990 cells, referred to as SW1990R. We then employed RNA-seq to explore the transcriptome changes between the gemcitabine-resistant cells and their parental counterparts.

ORGANISM(S): Homo sapiens

PROVIDER: GSE247165 | GEO | 2024/09/23

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Exploring Transcriptional alterations in the Development of Gemcitabine Resistance [AsPC1R_vs_AsPC1_RNAseq]

Project description:To investigate the transcriptional alterations that occur during the development of gemcitabine resistance in pancreatic cancer cells, we established gemcitabine-resistant AsPC1 cells, referred to as AsPC1R. We then employed RNA-seq to explore the transcriptome changes between the gemcitabine-resistant cells and their parental counterparts.

2024-09-23 | GSE247163 | GEO

Exploring Epigenetic Changes in the Development of Gemcitabine Resistance [SW1990R_vs_SW1990_ATACseq]

Project description:To elucidate the epigenetic events, particularly the dynamic alterations in chromatin accessibility during the development of gemcitabine resistance in pancreatic cancer cells, both the parental SW1990 cells and the gemcitabine-resistant counterparts, SW1990R cells, were employed for mapping of the chromatin accessibility landscape. The ATAC-seq technology was used for precise detection of chromatin accessibility.

2024-09-23 | GSE251994 | GEO

Exploring Epigenetic Changes in the Development of Gemcitabine Resistance [SW1990R_vs_SW1990_CUTTAG]

Project description:To elucidate the epigenetic events, particularly the dynamic alterations in chromatin states during the development of gemcitabine resistance in pancreatic cancer cells, both the parental SW1990 cells and the gemcitabine-resistant counterparts, SW1990R cells, were employed for mapping of the histone modification landscape. The CUT&Tag-seq technology was used for precise detection of histone marks, including H3K4me1 (associated with enhancers), H3K27ac (related to active enhancers and promoters), H3K4me3 (linked to PolII-bound and CpG-rich promoters), H3K9me3 (associated with heterochromatin regions), and H3K27me3 (indicative of Polycomb inhibition).

2024-09-23 | GSE247164 | GEO

Exploring Epigenetic Changes in the Development of Gemcitabine Resistance [SW1990R_vs_SW1990_RRBS]

Project description:To elucidate the DNA methylation alterations during the development of gemcitabine resistance in pancreatic cancer cells, we utilized both the parental SW1990 cells and their gemcitabine-resistant derivatives, SW1990R cells, to examine DNA methylation patterns. We employed reduced representation bisulfite sequencing (RRBS) assays to uncover the specific CpG methylation profiles.

2024-09-23 | GSE247167 | GEO

Exploring Epigenetic Changes in the Development of Gemcitabine Resistance [AsPC1R_vs_AsPC1_CUTTAG]

Project description:To elucidate the epigenetic events, particularly the dynamic alterations in chromatin states during the development of gemcitabine resistance in pancreatic cancer cells, both the parental AsPC1 cells and the gemcitabine-resistant counterparts, AsPC1R cells, were employed for mapping of the histone modification landscape. The CUT&Tag-seq technology was used for precise detection of histone marks, including H3K4me1 (associated with enhancers), H3K27ac (related to active enhancers and promoters), H3K4me3 (linked to PolII-bound and CpG-rich promoters), H3K9me3 (associated with heterochromatin regions), and H3K27me3 (indicative of Polycomb inhibition).

2024-09-23 | GSE247161 | GEO

Next-generation sequencing analysis of transcriptom in gemcitabine resistant pancreatic cancer cells

Project description:Next-generation sequencing was applied to compare the transcriptom of 1) SW1990 human pancreatic cancer cell lines and its gemcitabine-resistant derivative established with long-term exposure in medium containing 100 nM gemcitabine; 2) TRA-1-81+ cells and TRA-1-81- cells isolated from SW1990 human pancreatic cancer cell line.

2017-03-31 | GSE79953 | GEO

Gemcitabine Drug resistance

Project description:KBwt is a KB parental cell KBHURs is a hydroxyurea resistant KB clone KBGem is a gemcitabine resistant KB clone Keywords: HU95 V2

2007-08-30 | GSE3344 | GEO

Transcriptome and phosphoproteome analyses of gemcitabine-resistant gallbladder cancer cells provide novel insights into molecular changes occurring during acquired resistance

Project description:Treatment options for advanced gallbladder cancer (GBC) are scarce and usually rely on cytotoxic chemotherapy, but unfortunately the effectiveness of any regimen is limited, and recurrence rates are high. Here, we established and characterized two gemcitabine-resistant GBC cell sublines (NOZ GemR and TGBC1 GemR) to investigate the molecular mechanisms associated with acquired resistance in vitro. The transcriptome profiling of parental and gemcitabine resistant cells revealed differential expression of multiple protein-coding genes and enrichment of biological processes such as epithelial-to-mesenchymal transition and drug metabolism. On the other hand, quantitative phosphotyrosine proteomic analysis of NOZ GemR identified aberrantly dysregulated signaling pathways in resistant cells as well as active kinases, such as Abl, PDGFRA, EphB2 and members of the Src-family that could be novel therapeutic targets against drug resistance in GBC. In line with this, NOZ GemR cells showed increased sensitivity toward the multikinase inhibitor dasatinib compared with parental cells. In conclusion, our study describes transcriptome changes and altered signaling pathways occurring in gemcitabine-resistant gallbladder cancer cells, which greatly expands our understanding of the underlying mechanisms of acquired drug-resistance in GBC. Moreover, this new gemcitabine resistant GBC models could be exploited either to study alternative mechanisms of resistance or to explore new therapies for chemotherapy-refractory GBC.

2023-05-03 | PXD036348 | Pride

microRNA profiling by array of gemcitabine sensitive BxPC-3 pancreatic cancer cell lines and their derived resistant subclones, Bx-GEM

Project description:This experiment describes the differential microRNA expression between parental gemcitabine-sensitive BxPC-3 cells and their resistant subclones, Bx-GEM. To select for the resistant subclones, parental BxPC-3 cells were treated with increasing concentrations of gemcitabine (10, 25, 50, 100 and 200 nM) for more than one year. Cells resistant at each stage of drug dosing were re-cultured in the subsequent dose, and their resistance confirmed via cell viability assays. Subclones resistant to 200 nM gemcitabine, in additon to the parental cells were used for microRNA profiling by array. Total RNA was extracted from the cells using the miRNeasy Mini Kit (Qiagen). Fluorescently-labeled miRNA were prepared according to Agilent protocol miRNA Complete Labeling and Hyb Kit. Labeled miRNA sample were hybridized for at least 20 hr at 55C on Agilent human miRNA Microarray Release 19.0, 8x60k. Gene Expression Microarrays were scanned using the Agilent Scanner G2505C.

2017-01-20 | E-MTAB-4927 | biostudies-arrayexpress

Gene expression signature of gemcitabine resistance in human gastric cancer cell line

Project description:We examined the microarray-based expression profiles of the cells to identify genes associated with gemcitabine resistance Using a set of parental and gemcitabine resistant cell line, MKN28 and RMKN28, we studied mRNA transcription levels by microarray analysis to see if there are any of the key molecules for development of acquisition of the GEM resistance.

2015-05-01 | E-GEOD-58118 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data